|Podcasts|September 20, 2022
The Oncologist: Patient Conversation Must Include Clinical Trials
Author(s)Lisa Henderson, Andy Studna, Senior Editor
Dr. Shalaan Beg, VP of Oncology for Science 37, discusses his approach to reducing the time to trial activation at an NCI designated cancer center, how to ensure a diverse representation in clinical trials, and his opinion on decentralized and hybrid trials.
This podcast sponosored by
Related Content
Trending on Applied Clinical Trials Online
1
The Evolution of Preclinical CRO Strategic Partnerships: From Transactional Services to Value-Driven Ecosystems in 2026
2
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
3
Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data
4
How Clinical Teams Can Build Real Trust With Patient Advocacy Organizations
5